GlassScriptPhysician profile
Sarah S Bateman
NPI 1295298255
$570.75
in general payments reported to CMS, 2019-2025
15 companies · $22.64 in 2025
The $22.64 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $73.99 · 2023: $121 · 2024: $179 · 2025: $22.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $102.35 | 2023 | Oasis, Grafix Pl, Oasis Micro |
| Takeda Pharmaceuticals U.S.A., INC. | $71.50 | 2024 | Gattex |
| Pacira Pharmaceuticals Incorporated | $63.66 | 2024-2025 | Exparel |
| Si-Bone, INC. | $57.12 | 2021-2022 | |
| Innocoll Pharmaceuticals Limited | $50.36 | 2021 | |
| Boston Scientific Corporation | $43.11 | 2021 | |
| Stryker Corporation | $34.69 | 2022 | |
| Davol INC. | $28.55 | 2021 | |
| Ambu INC. | $21.18 | 2022 | |
| Enterra Medical, INC. | $19.68 | 2024 | |
| Silk Road Medical, INC. | $18.75 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Astrazeneca Pharmaceuticals LP | $18.56 | 2024 | Andexxa |
| Myriad Genetic Laboratories, INC. | $15.58 | 2024 | Myrisk |
| Integra Lifesciences Corporation | $12.87 | 2021 | |
| Merit Medical Systems INC | $12.79 | 2024 | Savi Scout |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bateman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.